Bioasis Provides Update on Business Operations
NEW HAVEN, Conn., March 23, 2023 (GLOBE NEWSWIRE) — BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factor and a differentiated, proprietary xB3 ™ platform for delivering therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need provides this update on its business operations.
Related news for (BIOAF)
- Bioasis Provides Corporate Update and Announces Suspension of Operations
- Bioasis Announces AGM Results and Provides Update on Financial Position
- Bioasis Technologies Inc. Announces Termination of Arrangement Agreement with Midatech Pharma plc
- Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending November 30, 2022